Tumour immunotherapy: the adjuvant treatment of the 21st century?
In the course of a century, tumour immunology has revealed a picture of a very complex immune system involving the recognition and eradication of malignancies. Many tumours evade the immune system, and understanding of tumour escape mechanisms is the key to a successful immunotherapy for cancer. A wide array of tumour immunotherapy modalities have been developed, many of which have reached the phase of clinical trials, with some satisfactory results. Based on the available clinical, data and the techniques available for further improvement, we analyse the prospects for the different treatment modalities, and predict an important role for tumour immunotherapy in the near future.
Bremers
A J
AJ
Unit of Human Tumour Immunotherapy, Istituto Nazionale dei Tumori, Milan, Italy.
Kuppen
P J
PJ
Parmiani
G
G
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000938:Antigen-Presenting Cells / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic; D015536:Down-Regulation; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm